Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Open access to large-scale drug discovery data

23.07.2008
Data on drugs and small molecules is placed in the the discovery and development of new medicines

The Wellcome Trust has awarded £4.7 million (€5.8 million) to EMBL’s European Bioinformatics Institute (EMBL-EBI) to support the transfer of a large collection of information on the properties and activities of drugs and a large set of drug-like small molecules from publicly listed company Galapagos NV to the public domain.

It will be incorporated into the EMBL-EBI’s collection of open-access data resources for biomedical research and will be maintained by a newly established team of scientists at the EMBL-EBI. These data lie at the heart of translating information from the human genome into successful new drugs in the clinic.

The human genome sequence provided a molecular ‘parts list’ for a human being, comprising all the genes and proteins that are encoded by our genetic blueprint. But to develop new medicines, it is important to catalogue how each of these ‘parts’ interacts with drugs and drug-like molecules. This interface of the genome with chemistry is a core part of the new scientific area of chemogenomics.

For the past eight years, researchers at BioFocus DPI, the service division of Galapagos, have been integrating the existing collections of information in these two areas to develop a set of well-structured chemogenomic databases that can be used to help determine whether a particular molecule has the right properties to make an effective drug. BioFocus DPI licensed this information to pharmaceutical and biotech companies worldwide. As part of the Wellcome Trust grant announced today, the EBI will obtain the rights to the databases from BioFocus DPI. The award will make it possible to provide free access to this information for all researchers. “The scientific community worldwide will greatly benefit from unrestricted access to these data.

It will aid their efforts in predictive drug discovery,” says Galapagos CEO Onno van de Stolpe. “Galapagos has successfully accelerated its research programmes with these, and BioFocus DPI used the data to deliver on its contracts with customers. After this transfer, which we hope will contribute to the advancement of drug discovery research by improving access to the data that we have collected, we will continue to use these resources.”

The transfer will empower academia to participate in the first stages of drug discovery for all therapeutic areas, including major diseases of the developing world. In future it could also result in improved prediction of drug side-effects. “We are excited to be able to provide information that defines the effects of a large number of small molecules on the body, and link this to the proteins that these molecules interact with, as part of our mission to provide wide access to bioinformatics tools to promote scientific progress and disseminate cutting-edge technologies to industry,” says EMBL-EBI Director Janet Thornton. “With this transfer, we aim to facilitate faster and better drug discovery. It speaks to the importance of this information for translational research that the Wellcome Trust has chosen to support this particular transfer with sufficient long-term funding.”

This unprecedented transfer of pharmaceutical data resources from the private sector to the public domain will have the greatest impact on researchers in academia and in small companies on limited budgets. “The Wellcome Trust has a strong commitment to making vital research tools freely available to the academic research community,” says Dr Alan Schafer, Head of Molecular and Physiological Sciences at theWellcome Trust. “Enabling these previously proprietary data to enter the public domain will allow researchers worldwide to make free use of knowledge essential for drug discovery.

Cath Brooksbank | alfa
Further information:
http://www.embl.org
http://www.embl.org/aboutus/news/press/2008/23jul08/index.html

More articles from Awards Funding:

nachricht Innovation Award of the United Nations Environment Programme for PhD Student from ZMT
22.03.2018 | Leibniz-Zentrum für Marine Tropenforschung (ZMT)

nachricht ERC Project set to boost application of adhesive structures
19.03.2018 | INM - Leibniz-Institut für Neue Materialien gGmbH

All articles from Awards Funding >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Explanation for puzzling quantum oscillations has been found

So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics

Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...

Im Focus: Dozens of binaries from Milky Way's globular clusters could be detectable by LISA

Next-generation gravitational wave detector in space will complement LIGO on Earth

The historic first detection of gravitational waves from colliding black holes far outside our galaxy opened a new window to understanding the universe. A...

Im Focus: Entangled atoms shine in unison

A team led by Austrian experimental physicist Rainer Blatt has succeeded in characterizing the quantum entanglement of two spatially separated atoms by observing their light emission. This fundamental demonstration could lead to the development of highly sensitive optical gradiometers for the precise measurement of the gravitational field or the earth's magnetic field.

The age of quantum technology has long been heralded. Decades of research into the quantum world have led to the development of methods that make it possible...

Im Focus: Computer-Designed Customized Regenerative Heart Valves

Cardiovascular tissue engineering aims to treat heart disease with prostheses that grow and regenerate. Now, researchers from the University of Zurich, the Technical University Eindhoven and the Charité Berlin have successfully implanted regenerative heart valves, designed with the aid of computer simulations, into sheep for the first time.

Producing living tissue or organs based on human cells is one of the main research fields in regenerative medicine. Tissue engineering, which involves growing...

Im Focus: Light-induced superconductivity under high pressure

A team of scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg investigated optically-induced superconductivity in the alkali-doped fulleride K3C60under high external pressures. This study allowed, on one hand, to uniquely assess the nature of the transient state as a superconducting phase. In addition, it unveiled the possibility to induce superconductivity in K3C60 at temperatures far above the -170 degrees Celsius hypothesized previously, and rather all the way to room temperature. The paper by Cantaluppi et al has been published in Nature Physics.

Unlike ordinary metals, superconductors have the unique capability of transporting electrical currents without any loss. Nowadays, their technological...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Save the date: Forum European Neuroscience – 07-11 July 2018 in Berlin, Germany

02.05.2018 | Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

 
Latest News

Supersonic waves may help electronics beat the heat

18.05.2018 | Power and Electrical Engineering

Keeping a Close Eye on Ice Loss

18.05.2018 | Information Technology

CrowdWater: An App for Flood Research

18.05.2018 | Information Technology

VideoLinks
Science & Research
Overview of more VideoLinks >>>